GleamWall
中文EN

ADIA Adia Med, Inc.

Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1160420 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin35.3%
Operating margin-38.0%
Net margin-41.5%
FCF margin-27.2%
EBITDA margin-37.5%

Returns

ROE-111.0%
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets60.4%
Debt / equity0.00x
Current ratio1.09x
Interest coverage-20.10x

Cash quality & payout

Operating cash flow / net income0.62x
Accruals ratio—
Payout ratio—
Capex / revenue1.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-31
Income statement
Revenue$454,385$388,585$176,275$178,550$332,048$118,146$71,764
Cost of revenue$233,404$202,805$108,698$230,341$128,563$92,223$57,712
Gross profit$220,981$185,780$67,577-$51,791$203,485$25,923$14,052
R&D expense$4,375$0—-$1,664$6,192$24,616—
SG&A expense$243,731$208,315$182,490$143,544$100,491$132,846$103,074
Operating income-$39,150-$44,971-$151,920-$218,563$79,200-$116,587-$110,544
Interest expense$13,990-$11,786$10,980$9,437$9,074$7,410$5,675
Pretax income-$53,015-$56,382-$162,525-$225,625$70,376-$123,997-$116,219
Income tax$0$0$0$0$0$0$0
Net income-$53,015-$56,382-$162,525-$225,625$70,376-$123,997-$116,219
EBITDA-$37,503-$43,528-$150,669-$217,599$80,462-$115,444-$109,770
EPS (basic)0.000.000.00—0.000.000.00
EPS (diluted)0.000.000.00—0.000.000.00
Weighted avg. shares (diluted)94.40M161.40M94.40M—158.17M89.64M95.90M
Balance sheet
Cash & equivalents$1.14M$128,115$136,716$79,392$154,002$115,099$37,463
Receivables$53,360$44,010$79,360$33,360———
Inventory$348,500——$25,025———
Current assets$1.56M$342,598$358,907$161,510———
PP&E, net$41,790$33,495$34,938$30,695———
Intangibles———$0———
Total assets$2.45M$744,054$776,868$594,826———
Current liabilities$1.44M$1.06M$1.11M$745,195———
Total liabilities$1.48M$1.12M$1.20M$852,500———
Shareholders' equity$970,404-$476,581-$420,199-$257,674-$74,301-$144,676-$90,679
Cash flow statement
Operating cash flow-$75,575-$109,041-$55,037-$70,707$59,020-$136,366-$31,175
Capital expenditure$9,941$1$5,494$1$0$13,199$0
Free cash flow-$85,516-$109,042-$60,531-$70,708$59,020-$149,565-$31,175
Investing cash flow-$9,941-$5,301-$5,494$537-$15,785-$14,009-$2,794
Financing cash flow$1.10M$105,741$117,855-$4,440-$4,332$228,011$65,109
Depreciation & amortization$1,647$1,443$1,251$964$1,262$1,143$774
Stock-based compensation$0$0$0$42,250$0$0$0

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.